Virginia Retirement Systems ET AL reduced its position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN – Get a rating) by 43.9% in Q1, according to the company in its latest 13F filing with the Securities and Exchange Commission (SEC). The institutional investor held 3,700 shares of the company after selling 2,900 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Biohaven Pharmaceutical were worth $439,000 when it last filed with the SEC.
Other hedge funds and other institutional investors have also recently increased or reduced their stakes in the company. National Bank of Canada FI acquired a new stake in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $28,000. Elkhorn Partners Limited Partnership acquired a new stake in Biohaven Pharmaceutical during Q4 valued at approximately $48,000. Montag A & Associates Inc. increased its position in Biohaven Pharmaceutical by 16.7% in the fourth quarter. Montag A & Associates Inc. now owns 804 shares of the company valued at $111,000 after purchasing an additional 115 shares during the period. Lindbrook Capital LLC acquired a new position in shares of Biohaven Pharmaceutical in the fourth quarter worth $113,000. Finally, Bay Colony Advisory Group Inc dba Bay Colony Advisors purchased a new stake in Biohaven Pharmaceutical stock during the fourth quarter at a value of $220,000. 88.03% of the shares are held by institutional investors.
Shares of Biohaven Pharmaceutical Stock opened at $145.55 on Monday. The company has a fifty-day simple moving average of $137.59 and a 200-day simple moving average of $127.71. The stock has a market capitalization of $10.27 billion, a price-earnings ratio of -12.29 and a beta of 1.10. Biohaven Pharmaceutical Holding Company Ltd. has a 12-month low of $79.01 and a 12-month high of $151.51.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly earnings data on Tuesday, May 10. The company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.45). The company posted revenue of $318.85 million for the quarter, versus a consensus estimate of $187.12 million. During the same period of the previous year, the company achieved EPS ($4.21). Analysts expect Biohaven Pharmaceutical Holding Company Ltd. shows earnings per share of -10.51 for the current year.
Several research analysts have recently commented on BHVN’s actions. HC Wainwright downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 research note. Cantor Fitzgerald downgraded Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 research report. Piper Sandler cut her price target on Biohaven Pharmaceutical shares from $156.00 to $149.00 and gave the stock an “na” rating in a Tuesday, May 24, report. Morgan Stanley lowered its price target on Biohaven Pharmaceutical shares from $148.00 to $146.00 and set an “equal weight” rating for the company in a Wednesday, April 6 report. Finally, SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “market performer” rating and set a price target of $150.00 for the stock. in a report from Wednesday, May 11. Five investment analysts gave the stock a hold rating and three gave the company a buy rating. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $157.33.
In other news from Biohaven Pharmaceutical, CAD George C. Clark sold 4,200 shares of Biohaven Pharmaceutical in a trade that took place on Tuesday, May 10. The stock was sold at an average price of $141.50, for a total transaction of $594,300.00. As a result of the transaction, the accounting chief now owns 4,065 shares of the company, valued at $575,197.50. The transaction was disclosed in an SEC filing, available at this link. Insiders of the company own 12.40% of the shares of the company.
About Biohaven Pharmaceutical (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Get news and reviews for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.